Xolair omalizumab regulatory update

FDA's Pulmonary-Allergy Drugs Advisory Committee will meet on Nov. 18 to discuss an sBLA from Genentech and Novartis for Xolair omalizumab to treat moderate to severe persistent asthma in patients age...